Viloxaznie: FDA approves Nonstimulant for ADHD in Kids 6 -17 Years
The US Food and Drug Administration (FDA) has approved the non-stimulant medication viloxazine extended-release capsules (Qelbree, Supernus Pharmaceuticals) for the treatment of (ADHD) in children aged 6 to 17 years, and adults. Viloxazine is a selective Nor-epinephrine reuptake inhibitor. Capsules may be swallowed whole or opened and the […]
Read More